<DOC>
	<DOCNO>NCT00563771</DOCNO>
	<brief_summary>To provide treatment opportunity child adolescent patient hematologic malignancy supply delay market product also observe efficacy safety rasburicase use treatment hyperuricemia</brief_summary>
	<brief_title>Rasburicase Treatment Hyperuricemia Children Adolescence Patients With Tumor Lysis Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Tumor Lysis Syndrome</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>Acute hyperuricemia patient / chemotherapy hematologic malignancy ( uric acid great 7.5 mg/dL ) With minimum life expectancy 3 month Having previously sign write informed consent . Hypersensitivity uricase excipients . Known history G6PD deficiency . Previous treatment Rasburicase Uricozyme . Treatment investigational drug within 30 day plan first Rasburicase administration . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>